CNTA
Centessa Pharmaceuticals plcNASDAQHealthcare$39.69-0.05%ClosedMarket Cap: $5.34B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
10.22
P/S
355.50
EV/EBITDA
-25.42
DCF Value
$0.65
FCF Yield
-3.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-1384.6%
Net Margin
-1316.9%
ROE
-50.7%
ROA
-28.7%
ROIC
-32.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-68.5M | $-66.2M | $-0.47 | — |
| FY 2025 | $15.0M | 100.0% | $-207.7M | $-197.5M | $-1.46 | — |
| Q3 2025 | $0.00 | NaN% | $-53.8M | $-54.9M | $-0.41 | — |
| Q2 2025 | $0.00 | NaN% | $-54.7M | $-50.3M | $-0.38 | — |
| Q1 2025 | $15.0M | 100.0% | $-30.8M | $-26.1M | $-0.20 | — |
| Q4 2024 | $0.00 | NaN% | $-74.6M | $-111.3M | $-0.84 | — |
| FY 2024 | $0.00 | NaN% | $-201.1M | $-235.8M | $-2.06 | — |
| Q3 2024 | $0.00 | NaN% | $-46.4M | $-42.6M | $-0.37 | — |
| Q2 2024 | $0.00 | NaN% | $-44.0M | $-43.8M | $-0.40 | — |
| Q1 2024 | $0.00 | NaN% | $-36.1M | $-38.0M | $-0.38 | — |
| Q4 2023 | $6.9M | 100.0% | $-35.2M | $-36.8M | $-0.38 | — |
| FY 2023 | $6.9M | 100.0% | $-171.3M | $-151.1M | $-1.57 | — |